TEVA Teva Pharmaceutical Industries Ltd

By Carlo Martuscelli

Indivior PLC (INDV.LN) said Wednesday that uptake of its next-generation opioid-addiction treatment Sublocade was increasing.

The pharmaceutical company said its making progress in reducing the time taken for the drug to be prescribed and administered, as well as improving payor coverage. It backed its guidance of between $25 million and $50 million in revenue from the drug in 2018, with sales weighted to the fourth quarter.

Indivior also said that Teva Pharmaceutical Industries Ltd. (TEVA.TV) has agreed to delay the entry of its rival generic opioid-addiction treatment, a buprenorphine and naloxone sublingual film, until a U.S. court rules on a preliminary injunction granted against Dr. Reddy's Laboratories Ltd. (RDY).

The injunction, granted in July, stopped Dr. Reddy's from introducing its own generic rival opioid-addiction drug to the market over a potential patent dispute. A court of appeals must now rule whether to uphold the ban, or allow the introduction of the generic to the market. A decision is expected in early November, Indivior said.

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com

(END) Dow Jones Newswires

September 12, 2018 03:00 ET (07:00 GMT)

Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 6 2024 まで 7 2024

Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 7 2023 まで 7 2024